Navigation Links
AFL To Return to Oklahoma Due to Overwhelming Demand for Signalife Heart Screening
Date:7/16/2008

LOS ANGELES, July 16 /PRNewswire-FirstCall/ -- Due to overwhelming demand for ambulatory heart tests performed by the Athletes for Life Foundation, Inc. ("AFL" or the "Foundation") using Signalife, Inc.'s (Amex: SGN) award winning Fidelity 100 ECG system, AFL is returning to Ada, Oklahoma, to perform more ECG tests at the request of the Chickasaw Nation and members of the local community. Andrea Pogue MSN, RN, Industrial Coordinator of the Pontotoc Technology Center ("PTC") of The Chickasaw Nation, said, "We are so happy you all decided to come to PTC and bring the trailer to perform life saving screenings."

Willie Gault, Super Bowl champion, Olympic gold medalist, and winner of the prestigious Jim Thorpe award, and one of the founders of Athletes For Life, said, "After our last ECG screenings at the Pontotoc Technology Center, performed as part of a program sponsored by the National Library of Medicine (NLM), a division of the National Institute of Health's (NIH), we were invited back to Ada, Oklahoma to expand our efforts to test both numerous people we were unable to test on our first visit as well as many new members of the public. In our first series of tests, we identified a life threatening condition in a local 16 year old, which on its own justifies our program. I plan to be back in Ada to help raise awareness about heart disease and visit with the young man and his family."

The Foundation is performing heart screening at its trailer at the Carl Albert Hospital until Friday July 18, and will then move its trailer to the Chickasaw Community Center to continue screening until July 26.

Athletes for Life Foundation has continued to select Signalife's award winning technology to perform its heart monitoring and screening. The Signalife monitor is a 12 lead ambulatory ECG system capable of detecting subtle ECG changes that may be significant for early diagnosis of potential heart problems.

About Athletes for Life Foundation

The Athletes for Life Foundation, http://www.athletesforlife.com, is a non-profit foundation whose membership includes a multitude of famous role models and athletes who have witnessed friends and colleagues die suddenly from cardiac disease. The Athletes for Life Foundation is committed to promoting early diagnosis and treatment of cardiac disease in order to save lives. The Athletes for Life Foundation is committed to bringing -- and does bring -- new technologies to healthcare. The Athletes for Life Foundation brings heart monitoring to communities, so that health care comes to the masses and not vice versa, in its mission to "save lives, one heart at a time."

About Signalife

Signalife, Inc., http://www.signalife.com, is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to develop medical devices that provide clear trusted data acquisition to enable accurate timely diagnosis of heart disease. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.signalife.com.

Caution Regarding Forward-Looking Statement

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NanoMedicine Summit Returns to Cleveland, September 25-26
2. Excalibur Celebrates PIramed Sale With Substantial Cash Return to Investors
3. Cystic Fibrosis Trial In Children Returns Positive Data
4. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
5. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
6. More Can Be Done Now to Address the Growing Global Demand for Grain
7. Liberty Screening Services Hires Top Executive to Meet Explosive Demand for its Background-Screening Services
8. Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand
9. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
10. Strong Demand Pushes up Both Prices and Sales Volumes for Dragons Main Products
11. Signalife Board Approves Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
(Date:2/16/2017)... 2017 UCHealth ( Aurora, Colorado ... pulmonary nodule patient management. In addition to optimizing care ... on the lung, UCHealth looks to improve provider workflow ... Stephanie Brown, RN , Thoracic Nurse ... with an Excel spreadsheet, which was extremely arduous and ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced today ... and Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at Andrews ... female physician suffering from degenerative disc disease with radiculomyelopathy, as a result of ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
Breaking Biology Technology:
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
(Date:2/3/2017)... A new independent identity strategy consultancy firm announces its ... to fill a critical niche in technical and policy ... Mark Crego and Janice Kephart together ... that span federal governments, the 9/11 Commission, private industry, ... has a common theme born from a shared passion ...
(Date:2/1/2017)... February 1, 2017 IDTechEx Research, a leading ... technology, announces the availability of a new report, Sensors for ... Continue Reading ... ... collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and ...
Breaking Biology News(10 mins):